Anaerobic bacteria in 118 patients with deep-space head and neck infections from the University Hospital of Maxillofacial Surgery, Sofia, Bulgaria

References

1. Aldridge K. E., Ashcraft D., Cambre K., Pierson C. L., Jenkins S. G., Rosenblatt J. E. 2001; Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group,Prevotella , Fusobacterium , Porphyromonas , and Peptostreptococcus species. Antimicrob Agents Chemother 45:1238–1243 [CrossRef]
   [Google Scholar]
2. Bahar H., Torun M. M., Demirci M., Kocazeybek B. 2005; Antimicrobial resistance and beta-lactamase production of clinical isolates of Prevotella and Porphyromonas species. Chemotherapy 51:9–14 [CrossRef]
   [Google Scholar]
3. Brook I. 2004; Microbiology and management of peritonsillar, retropharyngeal, and parapharyngeal abscesses. J Oral Maxillofac Surg 62:1545–1550 [CrossRef]
   [Google Scholar]
4. Dubreuil L., Houcke I., Singer E. 1999; Susceptibility testing of anaerobic bacteria: evaluation of the redesigned (version 96) bioMérieux ATB ANA device. J Clin Microbiol 37:1824–1828
   [Google Scholar]
5. Han J. K., Kerschner J. E. 2001; Streptococcus milleri : an organism for head and neck infections and abscess. Arch Otolaryngol Head Neck Surg 127:650–654 [CrossRef]
   [Google Scholar]
6. Huang T.-T., Tseng F.-Y., Yeh T.-H., Hsu C.-J., Chen Y.-S. 2006; Factors affecting the bacteriology of deep neck infection: a retrospective study of 128 patients. Acta Otolaryngol 126:396–401 [CrossRef]
   [Google Scholar]
7. Jousimies-Somer H., Summanen P., Citron D., Baron E. J., Wexler H. M., Finegold S. M. (editors) 2002 Wadsworth Anaerobic Bacteriology Manual Belmont, CA: Star Publishing;
   [Google Scholar]
8. Kato N., Tanaka K., Kato H., Watanabe K. 2000; In vitro activity of R-95867, the active metabolite of a new oral carbapenem, CS-834, against anaerobic bacteria. J Antimicrob Chemother 45:357–361 [CrossRef]
   [Google Scholar]
9. Koeth L. M., Good C. E., Appelbaum P. C., Goldstein E. J. C., Rodloff A. C., Claros M., Dubreuil L. J. 2004; Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 53:1039–1044 [CrossRef]
   [Google Scholar]
10. Kuriyama T., Karasawa T., Nakagawa K., Saiki Y., Yamamoto E., Nakamura S. 2000; Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 90:600–608 [CrossRef]
    [Google Scholar]
11. Kuriyama T., Karasawa T., Nakagawa K., Yamamoto E., Nakamura S. 2001; Incidence of β -lactamase production and antimicrobial susceptibility of anaerobic Gram-negative rods isolated from pus specimens of orofacial odontogenic infections. Oral Microbiol Immunol 16:10–15 [CrossRef]
    [Google Scholar]
12. Miller D. L., Brazer S., Murdoch D., Reller L. B., Corey G. R. 2001; Significance of Clostridium tertium bacteremia in neutropenic and nonneutropenic patients: review of 32 cases. Clin Infect Dis 32:975–978 [CrossRef]
    [Google Scholar]
13. National Committee for Clinical Laboratory Standards 2004 Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria , 6th edn. Approved standard M11-A6 Villanova, PA: NCCLS;
    [Google Scholar]
14. Papaparaskevas J., Pantazatou A., Katsandri A., Legakis N. J., Avlamis A. Hellenic Study Group for Gram-Negative Anaerobic Bacteria 2005; Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece. Clin Microbiol Infect 11:820–824 [CrossRef]
    [Google Scholar]
15. Peláez T., Alcalá L., Alonso R., Rodríguez-Créixems M., García-Lechuz J. M., Bouza E. 2002; Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46:1647–1650 [CrossRef]
    [Google Scholar]
16. Piérard D., Wybo I., Vandoorslaer K., Roebben E., Rosseel P., Lauwers S. 2003; In vitro activity of ertapenem against anaerobes isolated from the respiratory tract. Pathol Biol (Paris) 51:508–511 (in French [CrossRef]
    [Google Scholar]
17. Sobottka I., Cachovan G., Stürenburg E., Ahlers M. O., Laufs R., Platzer U., Mack D. 2002; In vitro activity of moxifloxacin against bacteria isolated from odontogenic abscesses. Antimicrob Agents Chemother 46:4019–4021 [CrossRef]
    [Google Scholar]
18. Speirs G., Warren R. E., Rampling A. 1988; Clostridium tertium septicemia in patients with neutropenia. J Infect Dis 158:1336–1340 [CrossRef]
    [Google Scholar]
19. Tiagunenko Y., Marina M. 1990; Instructions for microbiological diagnostics of diseases caused by clostridia. In Instructions for Microbiology Diagnostics of Bacterial Infections vol. 2 pp  183–194 Edited by Stoyanova M., Mitov G. Sofia: Centre for Scientific Information on Medicine and Healthcare;
    [Google Scholar]
20. Wexler H. M., Molitoris D., St John S., Vu A., Read E. K., Finegold S. M. 2002; In vitro activities of faropenem against 579 strains of anaerobic bacteria. Antimicrob Agents Chemother 46:3669–3675 [CrossRef]
    [Google Scholar]